Is 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl)? Is 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) safe for nursing mother and child? Does 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) extracts into breast milk? Does 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) has any long term or short term side effects on infants? Can 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) influence milk supply or can 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) decrease milk supply in lactating mothers?

Erythropoietin is a normal component of human milk. Methoxy polyethylene glycol-1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) is a synthetic form of erythropoietin that slowly releases the active drug, 1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl). The excretion of exogenous methoxy polyethylene glycol-1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) in breastmilk has not been studied; although the similar drug epoetin alfa has been studied and is considered to be acceptable during breastfeeding. If methoxy polyethylene glycol-1-165-Erythropoietin (human), monamide with alpha-(3-carboxypropyl)-omega-methoxypoly(oxy-1,2-ethanediyl) is required by the mother, it is not a reason to discontinue breastfeeding. However, since no information is available on its use during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. A study on Holder pasteurization of breastmilk found that the erythropoietin concentration in breastmilk dropped from about 1.9 international units/L before pasteurization to about 0.5 international units/L after pasteurization.[1]

Enhancement of gastrointestinal tract maturation has been proposed as a function of erythropoietin in breastmilk.[2][3]

In small studies, epoetin alfa administration decreased serum prolactin in patients with amylotrophic lateral sclerosis,[13] but had no effect in normal subjects or in patients with renal failure undergoing chronic ambulatory peritoneal dialysis.[14][15] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.